Post-earnings recap
Reported
Thu, May 7, 2015
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Acadia Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a slight decline in the stock price. The lack of revenue figures and guidance suggests uncertainty about the company's future performance. Investors may be cautious as management highlighted challenges in achieving profitability.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | -57.48% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions impacting performance. They did not provide any forward guidance, indicating uncertainty in the near term.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.